Get the Stockscreener App
3.87
2.76%
-0.11
Lantern Pharma Inc stock is traded at $3.87, with a volume of 77,455.
It is down -2.76% in the last 24 hours and down -14.76% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$3.98
Open:
$3.9
24h Volume:
77,455
Relative Volume:
0.50
Market Cap:
$42.12M
Revenue:
-
Net Income/Loss:
$-19.25M
P/E Ratio:
-2.1742
EPS:
-1.78
Net Cash Flow:
$-17.87M
1W Performance:
-0.51%
1M Performance:
-14.76%
6M Performance:
+10.89%
1Y Performance:
+10.89%
1-Day Range:
$3.75
$3.95
1-Week Range:
$3.70
$4.28
52-Week Range:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.90 | 42.98M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.58 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
653.07 | 69.37B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
480.83 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
832.20 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.06 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
How Lantern Pharma Inc. stock reacts to oil pricesWeekly Loss Report & Safe Capital Growth Tips - newser.com
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. - BioSpace
Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress - Digital Journal
Will Lantern Pharma Inc. stock recover after recent dropWeekly Risk Report & Growth-Oriented Investment Plans - newser.com
Using economic indicators to assess Lantern Pharma Inc. potentialIPO Watch & Target Return Focused Picks - newser.com
Lantern Pharma (LTRN) Reports Promising Phase 1 Trial Results for LP-284 - GuruFocus
Lantern Pharma presents LP-284 clinical data at 25th LL&M Congress - MarketScreener
Is Lantern Pharma Inc. stock attractive for income investorsInsider Selling & Weekly Return Optimization Plans - newser.com
What technical signals suggest for Lantern Pharma Inc. stockGDP Growth & Growth Focused Stock Pick Reports - Fundação Cultural do Pará
Is Lantern Pharma Inc. stock a buy before product launchesTrade Volume Summary & Advanced Technical Analysis Signals - newser.com
Lantern Pharma Inc. stock trendline breakdown2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com
Will Lantern Pharma Inc. stock maintain dividend yieldQuarterly Trade Summary & Real-Time Sentiment Analysis - newser.com
Why Lantern Pharma Inc. stock is favored by pension fundsTrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors - TipRanks
Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Lantern Pharma’s LP-184 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
When is the best time to exit Lantern Pharma Inc.July 2025 Price Swings & Free Weekly Chart Analysis and Trade Guides - newser.com
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025 - BioSpace
How to interpret RSI for Lantern Pharma Inc. stock2025 Macro Impact & AI Forecasted Stock Moves - newser.com
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
1.06%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):